GenMark Diagnostics (GNMK) Raised to “Hold” at ValuEngine

ValuEngine upgraded shares of GenMark Diagnostics (NASDAQ:GNMK) from a sell rating to a hold rating in a research report released on Friday.

A number of other equities analysts have also weighed in on GNMK. Canaccord Genuity lowered their price objective on shares of GenMark Diagnostics from $10.00 to $9.00 and set a buy rating on the stock in a research report on Tuesday, October 30th. BidaskClub upgraded shares of GenMark Diagnostics from a hold rating to a buy rating in a research report on Thursday, July 12th. Zacks Investment Research lowered shares of GenMark Diagnostics from a hold rating to a sell rating in a research report on Wednesday, October 17th. Finally, Needham & Company LLC reiterated a buy rating and issued a $11.00 price objective on shares of GenMark Diagnostics in a research report on Tuesday, July 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $10.33.

NASDAQ:GNMK opened at $4.90 on Friday. GenMark Diagnostics has a 1-year low of $3.63 and a 1-year high of $8.81. The company has a debt-to-equity ratio of 0.69, a quick ratio of 3.10 and a current ratio of 3.75. The firm has a market capitalization of $274.18 million, a P/E ratio of -4.05 and a beta of 1.26.

GenMark Diagnostics (NASDAQ:GNMK) last posted its quarterly earnings data on Monday, October 29th. The medical equipment provider reported ($0.20) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.20). GenMark Diagnostics had a negative net margin of 79.33% and a negative return on equity of 95.36%. The firm had revenue of $15.80 million for the quarter, compared to analyst estimates of $15.76 million. Analysts forecast that GenMark Diagnostics will post -0.86 earnings per share for the current fiscal year.

In other GenMark Diagnostics news, CEO Hany Massarany sold 6,203 shares of the firm’s stock in a transaction on Friday, August 24th. The stock was sold at an average price of $7.16, for a total value of $44,413.48. Following the completion of the sale, the chief executive officer now owns 682,491 shares of the company’s stock, valued at $4,886,635.56. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In the last three months, insiders sold 18,668 shares of company stock valued at $135,996. 7.09% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. Donaldson Capital Management LLC lifted its holdings in GenMark Diagnostics by 22.2% in the second quarter. Donaldson Capital Management LLC now owns 83,003 shares of the medical equipment provider’s stock valued at $530,000 after acquiring an additional 15,075 shares during the period. Russell Investments Group Ltd. lifted its holdings in GenMark Diagnostics by 10.7% in the second quarter. Russell Investments Group Ltd. now owns 172,512 shares of the medical equipment provider’s stock valued at $1,100,000 after acquiring an additional 16,611 shares during the period. Commonwealth Equity Services LLC acquired a new stake in GenMark Diagnostics in the second quarter valued at $115,000. Northern Trust Corp lifted its holdings in GenMark Diagnostics by 3.5% in the second quarter. Northern Trust Corp now owns 662,837 shares of the medical equipment provider’s stock valued at $4,229,000 after acquiring an additional 22,692 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in GenMark Diagnostics in the second quarter valued at $152,000. 99.28% of the stock is owned by institutional investors.

About GenMark Diagnostics

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

See Also: Is the Dow Jones Industrial Average (DJIA) still relevant?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply